| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445776 | European Journal of Cancer | 2012 | 9 Pages |
Abstract
Trabectedin demonstrates encouraging disease control in TRS. Since these promising results were generally noted in patients following chemotherapy, a phase III randomised trial in first-line is ongoing to compare trabectedin with doxorubicin-based chemotherapy in patients with TRS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Axel Le Cesne, Sara Cresta, Robert G. Maki, Jean Yves Blay, Jaap Verweij, Andrés Poveda, Paolo G. Casali, Carme Balaña, Patrick Schöffski, Federica Grosso, Pilar Lardelli, Antonio Nieto, Vicente Alfaro, George D. Demetri,